Kanada - İngilizce - Health Canada

boumatic llc - lactic acid; sodium chlorite - solution - 2.64%; 0.64% - lactic acid 2.64%; sodium chlorite 0.64% - cattle

Kanada - İngilizce - Health Canada

agrisan specialty chemical & pharmaceutical a division of agrisan inc - chlorhexidine acetate - solution - 0.5% - chlorhexidine acetate 0.5% - cattle

Kanada - İngilizce - Health Canada

liberchem inc. - chlorhexidine acetate; alcohol anhydrous - wipe - 0.002%; 50% - chlorhexidine acetate 0.002%; alcohol anhydrous 50% - cattle

Ermenistan - İngilizce - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

r-pharm germany gmbh - celecoxib - capsules - 200mg

Ermenistan - İngilizce - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

r-pharm germany gmbh - celecoxib - capsules - 100mg

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

brassica napus) pollen 500micrograms/ml solution for skin prick test (inmunotek - rapeseed (brassica napus) pollen allergen extract - solution for skin-prick test

Birleşik Arap Emirlikleri - İngilizce - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

medical scientific establishment united states of america - 1 test (1 test of 5 pads) - ivd test kit - device - gastrointestinal system-n/a

ABD - İngilizce - NLM (National Library of Medicine)

padagis us llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore, contraindicated (see warnings, cyp3a4 inhibitors ). dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant

ABD - İngilizce - NLM (National Library of Medicine)

bausch health us, llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - d.h.e. 45 (dihydroergotamine mesylate) injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore, contraindicated (see warnings, cyp3a4 inhibitors ). d.h.e. 45 (dihydroergotamine mesylate) injection, usp should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm includi

ABD - İngilizce - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings, cyp3a4  inhibitors ). dihydroergotamine mesylate injection should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see warnings). because dihydroergotamine mesylate injection may increase blood pressure, it should not be given to patients with uncontrolled hypertension. dihydroergotamine mesylate injection, 5-ht1 agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other. dihydroergotamine mesylate injection should not be administered to patients with hemiplegic or basilar migraine. in addition to those conditions mentioned above, dihydroergotamine mesylate injection is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery and severely impaired hepatic or renal function. dihydroergotamine mesylate injection is contraindicated in patients who have previously shown hypersensitivity to ergot alkaloids. dihydroergotamine mesylate should not be used with peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure.   currently available data have not demonstrated drug abuse or psychological dependence with dihydroergotamine. however, cases of drug abuse and psychological dependence in patients on other forms of ergot therapy have been reported. thus, due to the chronicity of vascular headaches, it is imperative that patients be advised not to exceed recommended dosages.